SAB01
/ Santa Ana Bio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 24, 2025
Pseudovitamin B12 producing Loigolactobacillus coryniformis enhances soy milk fermentation by Lactobacillus delbrueckii subsp. bulgaricus.
(PubMed, J Sci Food Agric)
- "Our findings in this study indicate that the growth of Lb. delbrueckii subsp. bulgaricus NBRC 13953 was promoted by the pseudovitamin B12 produced by Loigolactobacillus coryniformis SAB01, thereby suggesting a novel symbiotic relationship between these two lactic acid bacteria in soy milk."
Journal
June 13, 2024
Santa Ana Bio Launches With $168 Million to Advance Precision Medicines for Inflammatory Diseases
(Businesswire)
- "Santa Ana Bio...today emerged from stealth with $168 million in combined Series A and B funding. Founding investor Versant Ventures led the Series A round and was joined by TPG’s Life Science Innovations fund and GV. The $125 million Series B round was led by GV, with participation from all existing investors as well as new investors Access Biotechnology, Andreessen Horowitz (a16z) Bio + Health and RTW...The vast majority of biologics for autoimmune disease target cytokines, which are the messengers but not the causal agents. Nor do these treatments discriminate diseased from healthy tissue....SAB01 has been named as a development candidate, with Phase I testing expected to start next year in chronic inducible urticaria."
Financing • New P1 trial • Chronic Spontaneous Urticaria • Immunology • Inflammation • Inflammatory Bowel Disease
1 to 2
Of
2
Go to page
1